This ASX gold producer is undervalued due to limited production history, but strong early margins suggest significant profit potential and a possible near-term re-rating. It operates a low-risk open-pit mine with long reserves, resources, and added silver by-product exposure.
Acrow Limited is an Australian engineering and equipment rental company supplying formwork and scaffolding to construction and infrastructure projects. The business generates recurring income from its large hire fleet and has delivered strong revenue growth in recent years. Despite recent share price weakness, it offers solid cash flow and a fully franked dividend yield above 5%.
New Murchison Gold Limited is a small Australian gold producer operating the Crown Prince mine in Western Australia. The company recently transitioned from exploration to production and is generating strong cash flow from high-grade ore sold to Westgold Resources Limited. Exploration at nearby targets and potential underground mining could extend the project’s life and add future growth potential.
Rising geopolitical tensions and military modernisation are driving a surge in global defence spending, which exceeded US$2.6 trillion in 2025. Australia is also increasing defence investment, with spending expected to approach A$100 billion by 2034. As a result, ASX-listed companies involved in defence technology, shipbuilding and security systems are gaining investor attention as part of a long-term growth trend.
Electro Optic Systems develops remote weapon systems, counter-drone platforms and laser defence technologies for military customers. Despite strong order-book growth and rising defence demand, the company still generates operating losses and negative cash flow. Its valuation is largely based on future growth in counter-drone and directed-energy defence systems.
Racura Oncology is a clinical-stage biotech developing RC220 (bisantrene), a potential treatment for cancers such as AML and lung cancer. The company is pre-revenue and mainly funded through cash reserves and capital raises while advancing clinical trials. Its future valuation depends largely on trial results, regulatory progress and potential partnerships if the drug proves effective.
